Patents Assigned to Cellzome Limited
-
Patent number: 9655897Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.Type: GrantFiled: March 3, 2016Date of Patent: May 23, 2017Assignee: Cellzome LimitedInventors: Richard John Harrison, Nigel Ramsden, Jeremy Major, Adeline Morel, Laura Convery, Mihiro Sunose, Rosemary Lynch, Rita Adrego, Alison Jones
-
Patent number: 9296725Abstract: The present invention relates to compounds of formula (I) wherein R, R1, X1 to X5 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.Type: GrantFiled: May 23, 2013Date of Patent: March 29, 2016Assignee: Cellzome LimitedInventors: Richard John Harrison, Nigel Ramsden, Jeremy Major, Adeline Morel, Laura Convery, Mihiro Sunose, Rosemary Lynch, Rita Adrego, Alison Jones
-
Patent number: 9249129Abstract: The invention relates to compounds of formula (I) wherein X1, X2, R1 to R4, m, and n have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including the compounds, the preparation of such compounds as well as the use as medicaments.Type: GrantFiled: March 4, 2011Date of Patent: February 2, 2016Assignee: CELLZOME LIMITEDInventors: Jessica Taylor, Daniel Paul Hardy, Rosemary Lynch, Helen Sarah Niblock, Andrew David Cansfield
-
Patent number: 9242987Abstract: The invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.Type: GrantFiled: October 19, 2010Date of Patent: January 26, 2016Assignee: Cellzome LimitedInventors: Nigel Ramsden, Richard John Harrison, Sally Oxenford, Kathryn Bell, Nelly Piton, Claudio Dagostin, Cyrille Broussard, Andrew Ratcliffe
-
Patent number: 9242993Abstract: The invention relates to compounds of formula (I) wherein m, o, Ra, Rb, R1 and T1 have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including the compounds, the preparation of the compounds as well as their use as medicaments.Type: GrantFiled: October 5, 2012Date of Patent: January 26, 2016Assignee: CELLZOME LIMITEDInventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, John Thomas Feutrill, Rita Adrego, Katie Ellard, Tammy Ladduwahetty
-
Patent number: 9181245Abstract: The present invention is concerned with novel substituted 3,4-dihydro-2H-pyrido[1,2- a]pyrazine-1,6-dione derivatives of Formula (I) wherein R1, R2, R3, R4, R5, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: May 16, 2013Date of Patent: November 10, 2015Assignees: Janssen Pharmaceuticals, Inc., Cellzome LimitedInventors: Frederik Jan Rita Rombouts, Andrés Avelino Trabanco-Suarez, Henricus Jacobus Maria Gijsen, Gregor James MacDonald, François Paul Bischoff, Sergio-Alvar Alonso-de-Diego, Adriana Ingrid Velter, Yves Emiel Maria Van Roosbroeck
-
Patent number: 9145399Abstract: The present invention is concerned with novel substituted bicyclic triazole derivatives of Formula (I) wherein Het1, R1, R2, A1, A2, A3, A4, L1, and L2 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: January 12, 2011Date of Patent: September 29, 2015Assignees: Janssen Pharmaceuticals, Inc., Cellzome LimitedInventors: Michel Anna Jozef De Cleyn, Sven Franciscus Anna Van Brandt, Henricus Jacobus Maria Gijsen, Didier Jean-Claude Berthelot, Daniel Oehlrich
-
Patent number: 9115143Abstract: The present invention is concerned with novel substituted indole derivatives of Formula (I) wherein R1, R2, R3, A1, A2, A3, Y and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: July 12, 2012Date of Patent: August 25, 2015Assignees: Janssen Pharmaceuticals, Inc., Cellzome LimitedInventors: Garrett Berlond Minne, François Paul Bischoff, Henricus Jacobus Maria Gijsen, Adriana Ingrid Velter, Serge Maria Aloysius Pieters, Didier Jean-Claude Berthelot
-
Patent number: 9079886Abstract: The present invention is concerned with novel substituted triazole derivatives of Formula (I) wherein Het1, R1, R2, A1, A2, A3, A4, L1, and L2 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: January 12, 2011Date of Patent: July 14, 2015Assignees: Janssen Pharmaceuticals, Inc., Cellzome LimitedInventors: Sven Franciscus Anna Van Brandt, Michel Anna Jozef De Cleyn, Henricus Jacobus Maria Gijsen, Didier Jean-Claude Berthelot, Michel Surkyn
-
Patent number: 9040545Abstract: The present invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.Type: GrantFiled: August 12, 2011Date of Patent: May 26, 2015Assignee: Cellzome LimitedInventors: Kathryn Bell, Nelly Piton, Claudio Dagostin, Cyrille Boussard, Andrew Ratcliffe, Nigel Ramsden
-
Patent number: 8987276Abstract: The present invention is concerned with novel substituted triazolyl piperazine and triazolyl piperidine derivatives of Formula (I) wherein R1, R2, R3, R4a, R4b, R5, X, Y1, Y2, L1, and L2 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: March 22, 2012Date of Patent: March 24, 2015Assignees: Janssen Pharmaceuticals, Inc., Cellzome LimitedInventors: Francois Paul Bischoff, Adriana Ingrid Velter, Sven Franciscus Anna Van Brandt, Didier Jean-Claude Berthelot
-
Patent number: 8946266Abstract: The present invention is concerned with novel substituted triazole and imidazole derivatives of Formula (I) wherein R1, R2, A1, A2, A3, A4, X, and Het1 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: July 13, 2010Date of Patent: February 3, 2015Assignees: Janssen Pharmaceuticals, Inc., Cellzome LimitedInventors: Tongfei Wu, Henricus Jacobus Maria Gijsen, Frederik Jan Rita Rombouts, François Paul Bischoff, Didier Jean-Claude Berthelot, Daniel Oehlrich, Michel Anna Jozef De Cleyn, Serge Maria Aloysius Pieters, Garrett Berlond Minne, Adriana Ingrid Velter′, Sven Franciscus Anna Van Brandt, Michel Surkyn
-
Patent number: 8946426Abstract: The present invention is concerned with substituted bicyclic heterocyclic compounds of Formula (I) wherein Het1, Het2, A1, A2, A3 and A4 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: February 2, 2010Date of Patent: February 3, 2015Assignees: Janssen Pharmaceuticals, Inc., Cellzome LimitedInventors: Henricus Jacobus Maria Gijsen, Adriana Ingrid Velter, Gregor James MacDonald, François Paul Bischoff, Tongfei Wu, Sven Franciscus Anna Van Brandt, Michel Surkyn, Mirko Zaja, Serge Maria Aloysius Pieters, Didier Jean-Claude Berthelot, Michel Anna Jozef De Cleyn, Daniel Oehlrich
-
Publication number: 20140378438Abstract: The invention relates to compounds of formula (I) wherein m, n, R1, T0 and T1 have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds as well as methods of treating mTOR related diseases.Type: ApplicationFiled: September 21, 2012Publication date: December 25, 2014Applicant: CELLZOME LIMITEDInventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, Mihiro Sunose, Adeline Morel, Laura Convery, Rita Adrego
-
Patent number: 8835482Abstract: The present invention is concerned with novel substituted indazole and aza-indazole derivatives of Formula (I) wherein R1, R2, R3, R4, Y, A1, A2, A3, A4, X1, X2, X3 and Het1 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: May 5, 2010Date of Patent: September 16, 2014Assignees: Janssen Pharmaceuticals, Inc., Cellzome LimitedInventors: François Paul Bischoff, Henricus Jacobus Maria Gijsen, Serge Maria Aloysius Pieters, Garrett Berlond Minne
-
Patent number: 8785457Abstract: The invention relates to compounds of formula (I) wherein X, R1, R2, T, m, n, o have the meaning as cited in the description and the claims. The compounds of formula (I) are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.Type: GrantFiled: March 12, 2010Date of Patent: July 22, 2014Assignee: Cellzome LimitedInventors: Rosemary Lynch, Andrew David Cansfield, Helen Sarah Niblock, Daniel Hardy, Jane Elizabeth Scanlon, Rita Adrego, Nigel Ramsden
-
Patent number: 8772504Abstract: The present invention is concerned with novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives of Formula (I) wherein R1, R2, R3, R4, X, A1, A2, A3, A4, Y1, Y2, Y3 and Z have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: February 15, 2010Date of Patent: July 8, 2014Assignees: Janssen Pharmaceuticals, Inc., Cellzome LimitedInventors: Henricus Jacobus Maria Gijsen, François Paul Bischoff, Wei Zhuang, Sven Franciscus Anna Van Brandt, Michel Surkyn, Mirko Zaja, Didier Jean-Claude Berthelot, Michel Anna Jozef De Cleyn, Gregor James MacDonald, Daniel Oehlrich
-
Publication number: 20140179664Abstract: The present invention relates to compounds of formula (I) wherein X1 to X5, Z1 to Z3, Y0, RY1, RY2 and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.Type: ApplicationFiled: July 24, 2012Publication date: June 26, 2014Applicant: Cellzome LimitedInventors: Jay Freeman, Valerie Reader, Glynn Addison, Nigel Ramsden, Jane Elizabeth Scanlon, Richard John Harrison
-
Publication number: 20140163023Abstract: The invention relates to compounds of formula (I) wherein X, R1, R2, T0, o have the meaning as cited in the description and the claims. The compounds of formula I are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including the compounds of formula I, the preparation of such compounds as well as the use as medicaments.Type: ApplicationFiled: April 2, 2012Publication date: June 12, 2014Applicant: Cellzome LimitedInventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, Jane Elizabeth Scanlon, Rita Joana Rodrigues Adrego
-
Publication number: 20130190292Abstract: The present invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.Type: ApplicationFiled: August 12, 2011Publication date: July 25, 2013Applicant: CELLZOME LIMITEDInventors: Kathryn Bell, Nelly Piton, Claudio Dagostin, Cyrille Boussard, Andrew Ratcliffe, Nigel Ramsden